Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 219,400 shares, a growth of 11.7% from the March 31st total of 196,400 shares. Currently, 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 91,100 shares, the short-interest ratio is presently 2.4 days.

Wall Street Analysts Forecast Growth

AFMD has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on shares of Affimed to $10.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Monday, April 1st. StockNews.com started coverage on shares of Affimed in a research report on Tuesday, January 2nd. They set a “sell” rating for the company. Finally, Wells Fargo & Company reduced their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, April 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

Affimed Stock Down 2.6 %

AFMD opened at $5.35 on Wednesday. The company has a fifty day moving average price of $5.44 and a 200-day moving average price of $5.04. The firm has a market capitalization of $81.48 million, a P/E ratio of -0.64 and a beta of 2.05. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.25 and a quick ratio of 3.23. Affimed has a one year low of $2.23 and a one year high of $11.10.

Institutional Trading of Affimed

A number of hedge funds have recently made changes to their positions in AFMD. abrdn plc bought a new stake in shares of Affimed during the 4th quarter worth $130,000. EWA LLC bought a new stake in shares of Affimed during the 4th quarter worth $89,000. BNP Paribas Financial Markets lifted its holdings in shares of Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after acquiring an additional 163,162 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Affimed during the 4th quarter worth $341,000. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.